Arvinas Says First-in-Human Data for ARV-102 Shows Substantial Reduction of LRRK2

Important legal information about the email you will be sending. By using this service, you agree to input your real email address and only send it to people you know. It is a violation of law in some jurisdictions to falsely identify yourself in an email. All information you provide will be used by Fidelity solely for the purpose of sending the email on your behalf. The subject line of the email you send will be "Fidelity.com: "

Arvinas Says First-in-Human Data for ARV-102 Shows Substantial Reduction of LRRK2

, MT Newswires - 7:56 AM ET 4/4/2025 default

07:56 AM EDT, 04/04/2025 (MT Newswires) -- Arvinas ( ARVN ) said Friday that data from the first-in-human clinical trial of ARV-102 demonstrated substantial reduction of leucine-rich repeat kinase 2, or LRRK2, a multifunctional protein that has been primarily implicated in Parkinson's disease.

ARV-102 was generally safe and well tolerated with no serious adverse events reported after single or multiple doses, the company said.

At a single oral dose of at least 60 mg, and once daily repeated oral doses of at least 20 mg, ARV-102 achieved greater than 50% LRRK2 reduction in the cerebral spinal fluid and greater than 90% LRRK2 reduction in the peripheral blood mononuclear cells.

The company said its findings support continued evaluation of ARV-102 in neurodegenerative diseases associated with LRRK2 dysfunction and a phase 1 trial in patients with Parkinson's disease has been initiated and is currently enrolling.

MT Newswires does not provide investment advice. Unauthorized reproduction is strictly prohibited.